Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer - PubMed (original) (raw)
Clinical Trial
doi: 10.1097/JTO.0b013e3181fd42eb.
Robert N Raju, Thomas Stinchcombe, Darren M Kocs, Linda S Couch, David Barrera, Steven R Rousey, Janak K Choksi, Robert Jotte, Debra A Patt, Phillip O Periman, Howard R Schlossberg, Charles H Weissman, Yunfei Wang, Lina Asmar, Sharon Pritchard, Jane Bromund, Guangbin Peng, Joseph Treat, Coleman K Obasaju
Affiliations
- PMID: 21102260
- DOI: 10.1097/JTO.0b013e3181fd42eb
Free article
Clinical Trial
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
Mark A Socinski et al. J Thorac Oncol. 2010 Dec.
Free article
Abstract
Introduction: Enzastaurin is an oral serine/threonine kinase inhibitor that targets protein kinase C-beta (PKC-β) and the phosphatidylinositol-3-kinase/AKT pathway. This trial assessed pemetrexed-carboplatin ± enzastaurin to docetaxel-carboplatin in advanced non-small cell lung cancer.
Methods: Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1 were randomized to one of the three arms: (A) pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles with a loading dose of enzastaurin 1125 or 1200 mg followed by 500 mg daily until disease progression, (B) the same regimen of pemetrexed-carboplatin without enzastaurin, or (C) docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles. The primary end point was time to disease progression (TTP).
Results: Between March 2006 and May 2008, 218 patients were randomized. Median TTP was 4.6 months for pemetrexed-carboplatin-enzastaurin, 6.0 months for pemetrexed-carboplatin, and 4.1 months for docetaxel-carboplatin (differences not significant). Median survival was 7.2 months for pemetrexed-carboplatin-enzastaurin, 12.7 months for pemetrexed-carboplatin, and 9.2 months for docetaxel-carboplatin (log-rank p = 0.05). Compared with the other arms, docetaxel-carboplatin was associated with lower rates of grade 3 thrombocytopenia and anemia but a higher rate of grade 3 or 4 febrile neutropenia.
Conclusion: There was no difference in TTP between the three arms, but survival was longer with pemetrexed-carboplatin compared with docetaxel-carboplatin. Enzastaurin did not add to the activity of pemetrexed-carboplatin.
Trial registration: ClinicalTrials.gov NCT00308750.
Similar articles
- A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M. Rodrigues-Pereira J, et al. J Thorac Oncol. 2011 Nov;6(11):1907-14. doi: 10.1097/JTO.0b013e318226b5fa. J Thorac Oncol. 2011. PMID: 22005471 Clinical Trial. - Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N. Casey EM, et al. J Thorac Oncol. 2010 Nov;5(11):1815-20. doi: 10.1097/JTO.0b013e3181ee820c. J Thorac Oncol. 2010. PMID: 20881647 Clinical Trial. - Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J. Chiappori A, et al. J Thorac Oncol. 2010 Mar;5(3):369-75. doi: 10.1097/JTO.0b013e3181cee24f. J Thorac Oncol. 2010. PMID: 20090562 Clinical Trial. - Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Giaccone G, Peters GJ. Giovannetti E, et al. Curr Drug Targets. 2010 Jan;11(1):12-28. doi: 10.2174/138945010790031009. Curr Drug Targets. 2010. PMID: 19839931 Review. - Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Di BS, Wei KP, Tian JH, Xiao XJ, Li Y, Zhang XH, Yu Q, Yang KH, Ge L, Huang WH, Zhang FW. Di BS, et al. Asian Pac J Cancer Prev. 2014;15(8):3419-24. doi: 10.7314/apjcp.2014.15.8.3419. Asian Pac J Cancer Prev. 2014. PMID: 24870732 Review.
Cited by
- Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds.
Blanchard CE, Gomeiz AT, Avery K, Gazzah EE, Alsubaie AM, Sikaroodi M, Chiari Y, Ward C, Sanchez J, Espina V, Petricoin E, Baldelli E, Pierobon M. Blanchard CE, et al. Cell Commun Signal. 2024 Jul 26;22(1):377. doi: 10.1186/s12964-024-01742-3. Cell Commun Signal. 2024. PMID: 39061010 Free PMC article. - An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis.
Zhang C, Zhou W, Zhang D, Ma S, Wang X, Jia W, Guan X, Qian K. Zhang C, et al. Open Med (Wars). 2023 Feb 14;18(1):20220574. doi: 10.1515/med-2022-0574. eCollection 2023. Open Med (Wars). 2023. PMID: 36820064 Free PMC article. - Is area under the curve the best parameter for carboplatin induced emetic risk stratification?
Ozone S, Ichikawa K, Morise M, Matsui A, Kinoshita F, Matsuzawa R, Koyama J, Tanaka I, Hashimoto N. Ozone S, et al. Nagoya J Med Sci. 2021 Nov;83(4):773-785. doi: 10.18999/nagjms.83.4.773. Nagoya J Med Sci. 2021. PMID: 34916721 Free PMC article. - Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.
Sadeghi MM, Salama MF, Hannun YA. Sadeghi MM, et al. Int J Mol Sci. 2021 May 24;22(11):5527. doi: 10.3390/ijms22115527. Int J Mol Sci. 2021. PMID: 34073823 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical